menu
    • menu
    [{"orgOrder":0,"company":"Palladio Zannini Industrie","sponsor":"Samsara BioCapital","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"ITALY","productType":"Other Small Molecule","year":"2020","type":"Series B Financing","leadProduct":"Lixivaptan","moa":"V2R","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Palladio Zannini Industrie","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Palladio Zannini Industrie \/ Samsara BioCapital","highestDevelopmentStatusID":"10","companyTruncated":"Palladio Zannini Industrie \/ Samsara BioCapital"},{"orgOrder":0,"company":"Centessa Pharmaceuticals","sponsor":"General Atlantic","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Series A Financing","leadProduct":"Lixivaptan","moa":"V2R","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Centessa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Centessa Pharmaceuticals \/ General Atlantic","highestDevelopmentStatusID":"10","companyTruncated":"Centessa Pharmaceuticals \/ General Atlantic"},{"orgOrder":0,"company":"Centessa Pharmaceuticals","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Public Offering","leadProduct":"Lixivaptan","moa":"V2R","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Centessa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Centessa Pharmaceuticals \/ Morgan Stanley","highestDevelopmentStatusID":"10","companyTruncated":"Centessa Pharmaceuticals \/ Morgan Stanley"},{"orgOrder":0,"company":"Centessa Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lixivaptan","moa":"V2R","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Centessa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Centessa Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Centessa Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Palladio Biosciences","sponsor":"Centessa Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lixivaptan","moa":"V2R","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Palladio Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Palladio Biosciences \/ Centessa Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Palladio Biosciences \/ Centessa Pharmaceuticals"},{"orgOrder":0,"company":"Palladio Biosciences","sponsor":"Centessa Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lixivaptan","moa":"V2R","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Palladio Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Palladio Biosciences \/ Centessa Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Palladio Biosciences \/ Centessa Pharmaceuticals"},{"orgOrder":0,"company":"Centessa Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lixivaptan","moa":"V2R","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Centessa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Centessa Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Centessa Pharmaceuticals \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Lixivaptan

    Menu

    Lixivaptan

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
    filter

    Year

    filter

    DEALS // DEV.

    filter

    Country

    filter
    Sponsor
    filter

    Therapeutic Area

    filter

    Study Phase

    filter

    Deal Type

    filter

    Product Type

    filter

    Dosage Form

    filter

    Lead Product

    filter

    Target

    refresh Filters
    refresh Reset Filter
    refresh Reset Filter
    price-trend All Developments

    Therapeutic Area by Lead Product

    ForexGraph

    Study Phase by Lead Product

    ForexGraph

    Company by Lead Product

    ForexGraph

    Top Deals by Deal Size (USD bn)

    ForexGraph

    01

    Centessa Pharmaceuticals

    U.S.A arrow
    BePharma
    Not Confirmed

    Centessa Pharmaceuticals

    U.S.A arrow
    BePharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Lixivaptan

    Therapeutic Area : Genetic Disease

    Study Phase : Phase III

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Centessa Pharmaceuticals Doses First Subject in a Global Phase 3 ACTION Study of Lixivaptan in Autosomal Domin...

    Details : The start of dosing in the ACTION Study, designed to serve as a single registration trial and will evaluate the efficacy and safety of VPA-985 (lixivaptan), a nonpeptide selective vasopressin V2 receptor antagonist, in a broad group of ADPKD patients.

    Product Name : VPA-985

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    February 24, 2022

    Lead Product(s) : Lixivaptan

    Therapeutic Area : Genetic Disease

    Highest Development Status : Phase III

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    02

    Centessa Pharmaceuticals

    U.S.A arrow
    BePharma
    Not Confirmed

    Centessa Pharmaceuticals

    U.S.A arrow
    BePharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Lixivaptan

    Therapeutic Area : Genetic Disease

    Study Phase : Phase III

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Centessa Pharmaceuticals Makes Strategic Decision to Discontinue Clinical Development of Lixivaptan for Autoso...

    Details : Decision is based on reassessment of commercial potential of VPA-985 (lixivaptan) as potential best-in-class therapy for patients with ADPKD, following recent observation of alanine aminotransferase and aspartate aminotransferase elevations in ALERT Stud...

    Product Name : VPA-985

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    February 06, 2022

    Lead Product(s) : Lixivaptan

    Therapeutic Area : Genetic Disease

    Highest Development Status : Phase III

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    03

    Centessa Pharmaceuticals

    U.S.A arrow
    BePharma
    Not Confirmed

    Centessa Pharmaceuticals

    U.S.A arrow
    BePharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Lixivaptan

    Therapeutic Area : Genetic Disease

    Study Phase : Phase III

    Sponsor : Morgan Stanley

    Deal Size : $330.0 million

    Deal Type : Public Offering

    DEALS_DEV arrow-down

    Centessa Announces Pricing of Initial Public Offering

    Details : Lixivaptan (VPA-985) is an orally active and selective vasopressin receptor V2 antagonist, with IC50 values of 1.2 and 2.3 nM for human and rat V2, respectively.

    Product Name : VPA-985

    Product Type : Other Small Molecule

    Upfront Cash : Undisclosed

    May 27, 2021

    Lead Product(s) : Lixivaptan

    Therapeutic Area : Genetic Disease

    Highest Development Status : Phase III

    Sponsor : Morgan Stanley

    Deal Size : $330.0 million

    Deal Type : Public Offering

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    04

    Centessa Pharmaceuticals

    U.S.A arrow
    BePharma
    Not Confirmed

    Centessa Pharmaceuticals

    U.S.A arrow
    BePharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Lixivaptan

    Therapeutic Area : Genetic Disease

    Study Phase : Phase III

    Sponsor : General Atlantic

    Deal Size : $250.0 million

    Deal Type : Series A Financing

    DEALS_DEV arrow-down

    Centessa Pharmaceuticals Launches with $250 Million Series A Financing and Unveils a New Kind of Pharmaceutica...

    Details : Centessa Pharmaceuticals portfolio consists of four clinical stage programs, including two that are in late-stage clinical development. Palladio Biosciences, a subsidiary of Centessa, is developing lixivaptan, an oral non-peptide of kidney diseases.

    Product Name : VPA-985

    Product Type : Other Small Molecule

    Upfront Cash : Undisclosed

    February 16, 2021

    Lead Product(s) : Lixivaptan

    Therapeutic Area : Genetic Disease

    Highest Development Status : Phase III

    Sponsor : General Atlantic

    Deal Size : $250.0 million

    Deal Type : Series A Financing

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    05

    Palladio Biosciences

    U.S.A arrow
    BePharma
    Not Confirmed

    Palladio Biosciences

    U.S.A arrow
    BePharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Lixivaptan

    Therapeutic Area : Genetic Disease

    Study Phase : Phase III

    Sponsor : Centessa Pharmaceuticals

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Palladio Biosciences Doses First Patient With Lixivaptan in The ALERT Study

    Details : The ALERT Study, designed to assess the safety of lixivaptan in autosomal dominant polycystic kidney disease (ADPKD) patients who previously discontinued therapy with tolvaptan due to liver toxicity, is currently recruiting patients in the United States.

    Product Name : VPA-985

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    November 17, 2020

    Lead Product(s) : Lixivaptan

    Therapeutic Area : Genetic Disease

    Highest Development Status : Phase III

    Sponsor : Centessa Pharmaceuticals

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    06

    Palladio Biosciences

    U.S.A arrow
    BePharma
    Not Confirmed

    Palladio Biosciences

    U.S.A arrow
    BePharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Lixivaptan

    Therapeutic Area : Genetic Disease

    Study Phase : Phase III

    Sponsor : Centessa Pharmaceuticals

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Palladio Biosciences Announces Presentation of Data from a Study of Lixivaptan Use in an ADPKD Patient who Pre...

    Details : The presentation will include the results of more than 12 months of safe treatment with lixivaptan in this study, which was conducted as an expanded access clinical study under an IND.

    Product Name : VPA-985

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    October 20, 2020

    Lead Product(s) : Lixivaptan

    Therapeutic Area : Genetic Disease

    Highest Development Status : Phase III

    Sponsor : Centessa Pharmaceuticals

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    07

    Palladio Zannini Industrie

    Italy arrow
    BePharma
    Not Confirmed

    Palladio Zannini Industrie

    Italy arrow
    BePharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Lixivaptan

    Therapeutic Area : Genetic Disease

    Study Phase : Phase III

    Sponsor : Samsara BioCapital

    Deal Size : $20.0 million

    Deal Type : Series B Financing

    DEALS_DEV arrow-down

    Palladio Completes $20 Million Series B Financing

    Details : Proceeds from the financing will fund Palladio’s Phase 3 ALERT Study and advance operations.

    Product Name : VPA-985

    Product Type : Other Small Molecule

    Upfront Cash : Undisclosed

    September 25, 2020

    Lead Product(s) : Lixivaptan

    Therapeutic Area : Genetic Disease

    Highest Development Status : Phase III

    Sponsor : Samsara BioCapital

    Deal Size : $20.0 million

    Deal Type : Series B Financing

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth